NRXP NRX Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. a clinical-stage, small molecule pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was incorporated in 2015 and is headquartered in Wilmington, Delaware.

$1.18  +0.01 (0.86%)
As of 02/01/2023 16:00:00 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  12/04/2017
Outstanding shares:  67,690,914
Average volume:  337,493
Market cap:   $84,613,643
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BL5F9Z4

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%